Sucampo Sets Terms

Sucampo Pharmaceuticals Inc., a Bethesda, Md.-based developer of drugs based on prostones, a class of compunds, today set the terms of its IPO of 3.75 million Class A common shares at an estimated price of $14 to $16 per share. The company plans to list on the Nasdaq under the symbol SCMP. Cowen & Co., CIBC World Markets and Leerink Swann & Co. are serving as underwriters. The company raised $25 million in venture funding from such firm as Diamond Capital, Fujisawa Research Institute of America, Intel Capital and Mizuho Capital Co.